At a glance: your weight loss injection options in Australia
- Wegovy (semaglutide 2.4 mg, weekly) — TGA-indicated for chronic weight management. Typical trial averages ~10–15%+ body-weight reduction with lifestyle support. See Wegovy guide.
- Ozempic (semaglutide, weekly) — Indicated for type 2 diabetes; sometimes prescribed off-label for weight management. Ongoing, intermittent supply constraints have occurred. See Ozempic guide.
- Mounjaro (tirzepatide, weekly) — Dual GLP-1/GIP agonist indicated for type 2 diabetes; off-label weight management is clinician-dependent. Trials have shown ~15–22% averages at higher doses. See Mounjaro guide.
- Saxenda (liraglutide, daily) — Older GLP-1 for weight management. Typically lower average reductions vs weekly options; daily injections. See Saxenda guide.
- Other GLP-1s for diabetes (e.g., Trulicity/dulaglutide, Rybelsus/oral semaglutide) — Not TGA-indicated for weight loss; prescriber judgement applies.
Choosing comes down to indication, availability, expected results, dosing preference and your medical history.
How GLP-1 and dual-agonist injections aid weight loss
- Appetite and satiety: Slower gastric emptying and central satiety signalling help reduce calorie intake.
- Glycaemic control: Improved insulin response and lower post-meal glucose can reduce hunger swings.
- Dual agonism (tirzepatide): Adds GIP activity to GLP-1, which in trials has translated to greater average weight reduction for many participants.
These are prescription-only medicines with dose-escalation schedules to improve tolerability. They are intended to be used alongside nutrition, activity and behaviour strategies for sustained outcomes.
Who may be eligible in Australia
- Adults with BMI ≥30, or BMI ≥27 with weight-related comorbidities (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea).
- Readiness to combine medication with diet, activity and habit support.
- No contraindications such as certain endocrine tumours, pancreatitis history, or pregnancy. Your clinician will assess risks and interactions.
Prescribers follow TGA-approved indications where applicable; any off-label use (e.g., Ozempic or Mounjaro for weight management) is at the clinician’s discretion and patient-specific.
Results: what studies typically report
- Semaglutide 2.4 mg (Wegovy): Around 10–15%+ average body-weight reduction at ~68 weeks in clinical trials with lifestyle support. See semaglutide results timeline.
- Tirzepatide (Mounjaro): Approximately 15–22% average reductions at higher doses in trials. See tirzepatide results timeline.
- Liraglutide (Saxenda): Often ~5–8% on average in trials when combined with diet and activity.
Individual outcomes vary. Weight regain can occur if medication is stopped without durable behaviour and nutrition changes. Ongoing care matters.
Side effects, warnings and safety basics
- Common: Nausea, vomiting, diarrhoea, constipation, reflux, abdominal discomfort—often improve as doses are titrated gradually.
- Serious warnings: Risk of gallbladder disease, possible pancreatitis; GLP-1 RAs carry a boxed warning about thyroid C‑cell tumours (contraindicated with relevant personal/family history of MTC or MEN2).
- Interactions/considerations: Certain diabetes medicines, dehydration risks, alcohol use, and pregnancy/breastfeeding status must be reviewed with your doctor.
Seek prompt medical advice for severe abdominal pain, signs of dehydration, persistent vomiting, or yellowing of the skin/eyes. Read brand-specific Consumer Medicine Information (CMI) and follow clinician guidance.
Explore brand pages for details: Ozempic side effects, Wegovy side effects, Mounjaro side effects, Saxenda side effects.
Costs, PBS status and supply in Australia
- PBS: Subsidies generally apply to type 2 diabetes indications, not weight-loss indications. Private scripts for weight management are usually not PBS-subsidised.
- Pricing: Costs vary by brand, dose, pharmacy and consult fees. See detailed pages: Wegovy cost, Ozempic cost, Mounjaro cost, Saxenda cost.
- Consult and care fees: Initial consults, follow-ups, pathology and coaching can add to total program cost—ask for a full quote up front.
- Supply: Australia has experienced intermittent shortages (especially Ozempic). Prescribers can advise current availability and suitable alternatives.
How to access weight loss injections in Australia
- GPs and specialists: Many assess eligibility and prescribe when appropriate. Ask about brand choice, dose-escalation, monitoring and follow-up plans.
- Telehealth: Virtual clinics can streamline access and ongoing reviews. See Online Peptide Clinic Australia and Telehealth Peptide Clinic Australia to understand how remote care works.
- Avoid grey-market offers: Be cautious of unapproved imports or “research” products. Review Australian legal basics and counterfeit risks.
- Compounded GLP-1s: The TGA has scrutinised compounded semaglutide/tirzepatide. Discuss TGA-approved pathways with registered prescribers and avoid promotional claims from non-compliant vendors.
Choosing between Wegovy, Ozempic, Mounjaro and Saxenda
- Indication: Prefer TGA-indicated options for weight management where available (e.g., Wegovy). Off-label use is prescriber-dependent.
- Expected outcomes: Evidence suggests higher average losses with semaglutide 2.4 mg and tirzepatide vs older daily liraglutide.
- Dosing preference: Weekly vs daily injections; oral options exist for diabetes (Rybelsus), not for weight-loss indication.
- Tolerability: If GI effects limit one brand, discuss alternatives and titration strategies.
- Supply and cost: Real-world access and pricing can decide between otherwise comparable choices.
Deeper comparisons: Semaglutide vs Tirzepatide, Wegovy vs Saxenda, Mounjaro vs Ozempic, Wegovy vs Mounjaro, Ozempic vs Wegovy.
What’s next: dual and triple-agonist pipeline
- Retatrutide (triple agonist): Early trials suggest substantial weight reduction; still investigational in Australia. Learn more: What is Retatrutide?, retatrutide benefits, retatrutide vs tirzepatide.
- Cagrilintide (amylin analogue): Appetite-regulating mechanism; being studied solo and combined with semaglutide. See what is cagrilintide, cagrilintide vs semaglutide, cagrilintide vs tirzepatide.
Frequently asked questions
Which injections actually have a weight-loss indication?
As at recent updates, Wegovy (semaglutide 2.4 mg) and Saxenda (liraglutide) carry weight management indications. Ozempic (semaglutide), Mounjaro (tirzepatide), Rybelsus (oral semaglutide) and Trulicity (dulaglutide) are indicated for type 2 diabetes; off-label weight management, if considered, is clinician-dependent. See each brand page for current details.
How long until I notice changes?
Many people report appetite changes in the first 1–4 weeks as doses escalate. Meaningful weight change generally accumulates over months. Learn more in semaglutide results timeline and tirzepatide results timeline.
Can I switch if one brand doesn’t suit me?
Sometimes. Doctors may consider alternatives or adjusted titration if side effects or results are not meeting goals. Do not switch, stop or start medicines without medical guidance.
Do I need to stay on it forever?
Long-term use is common in trials and practice, but plans are personalised. If stopping, weight regain risk is higher without durable nutrition and behaviour changes. Discuss exit strategies with your clinician.
Is there an oral weight loss option?
Rybelsus is oral semaglutide for type 2 diabetes, not for a weight-loss indication in Australia. Research continues into oral and multi-agonist approaches for weight management.
Where can I learn about legal access and red flags?
Start here: Are peptides legal in Australia?, Buy semaglutide Australia, Buy tirzepatide Australia, and Counterfeit peptides guide.
Get help comparing Australian weight loss injections
Request a call or email from a clinic that can discuss eligibility, availability, pricing and next steps. No commitment required.
Prefer to reach out directly? Contact us.
Key takeaways
- Wegovy and Saxenda have weight management indications; Ozempic and Mounjaro are diabetes medicines that clinicians may consider off-label.
- Average results vary: tirzepatide and semaglutide 2.4 mg have shown higher averages than older daily options when paired with lifestyle support.
- PBS generally does not subsidise weight-loss indications; ask for a full cost breakdown and availability plan.
- Discuss safety, side effects and a long-term strategy with a registered prescriber before starting.